News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bausch & Lomb Announces Extension of Early Tender Date for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes Due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)


8/7/2012 9:46:45 AM

ROCHESTER, N.Y., Aug. 6, 2012 /PRNewswire/ -- Bausch & Lomb Incorporated ("Bausch + Lomb") announced today an amendment to its previously announced tender offer (the "tender offer") to purchase for cash up to $300 million of its outstanding 9 percent Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8) (the "senior notes").

Bausch + Lomb is extending the previously announced "early tender date" of 5 p.m., New York City time, on August 3, 2012, to 11:59 p.m., New York City time, on August 17, 2012, which is also the previously announced expiration date (such time and date, as the same may be extended or earlier terminated, the "expiration date") for the tender offer. All other terms of the tender offer remain unchanged.

Accordingly, holders of senior notes who validly tender their senior notes before the expiration date will be eligible to receive the previously announced "total consideration" of $1,041.25 per $1,000 principal amount of senior notes purchased.

The previously announced withdrawal deadline of 5 p.m., New York City time, on August 3, 2012 has passed. As a result, holders who have previously tendered senior notes and those holders who tender senior notes on or before the expiration date may not withdraw those notes.

The obligation of Bausch + Lomb to accept for purchase, and to pay for, senior notes validly tendered pursuant to the tender offer is subject to, and conditioned upon, the satisfaction or waiver of certain conditions as set forth in the Bausch + Lomb Offer to Purchase dated July 23, 2012, including completion of the drawdown of Bausch + Lomb's delayed draw term loan and other customary conditions.

The complete terms and conditions of the tender offer are described in the Bausch + Lomb Offer to Purchase dated July 23, 2012, copies of which may be obtained by contacting Global Bondholder Services Corporation, which is acting as the tender and information agent for the tender offer (the "tender and information agent"), at (866) 470-4500 (toll-free). Bausch + Lomb has engaged Citigroup to serve as dealer manager for the tender offer (the "dealer manager"). Questions regarding the terms of the tender offer may be directed to Citigroup at (800) 558-3745 (toll-free) or (212) 723-6106 (collect).

None of Bausch + Lomb, the dealer manager or the tender and information agent make any recommendation as to whether holders should tender their senior notes pursuant to the tender offer, and no one has been authorized by any of them to make any such recommendation. Holders must make their own decision as to whether to tender senior notes, and, if so, the principal amount of senior notes to tender.

This press release does not constitute an Offer to Purchase or a solicitation of an Offer to Sell our senior notes or other securities, nor shall there be any purchase of senior notes in any state or jurisdiction in which such offer, solicitation or purchase would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The tender offer is being made solely by and pursuant to the Bausch + Lomb Offer to Purchase dated July 23, 2012.

About Bausch + Lomb

Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, NY, and employs more than 11,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.

Forward-Looking Statements

Some of the statements in this press release and in Bausch + Lomb's Offer to Purchase contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the "Securities Act," and Section 21E of the Securities Exchange Act of 1934, as amended, or the "Exchange Act." Forward-looking statements are often characterized by the use of words such as "believe," "estimate," "expect," "project," "may," "intend," "plan" or "anticipate." Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause Bausch + Lomb's actual results, performance or achievements to be materially different from historical results, any future results, or performance or achievements expressed or implied by such forward-looking statements. When considering these forward-looking statements, holders of senior notes should keep in mind the cautionary statements in the Offer to Purchase. In addition, new risks and uncertainties may arise from time to time. Accordingly, all forward-looking statements should be evaluated with an understanding of their inherent uncertainty. All subsequent written and oral forward-looking statements attributable to Bausch + Lomb or persons acting on Bausch + Lomb's behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included herein are made only as of the date of this press release, and Bausch + Lomb does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

News Media Contact:

Adam Grossberg
Global Communications, Bausch + Lomb
(585) 338-8550 or Adam.Grossberg@bausch.com

SOURCE Bausch + Lomb


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES